Short Interest in CalciMedica Inc. (NASDAQ:CALC) Decreases By 60.5%

CalciMedica Inc. (NASDAQ:CALC) was the recipient of a significant decrease in short interest during the month of August. As of August 31st, there was short interest totaling 127,684 shares, a decrease of 60.5% from the August 15th total of 323,241 shares. Based on an average trading volume of 99,862 shares, the short-interest ratio is currently 1.3 days. Approximately 2.6% of the company’s stock are sold short.

Insider Activity at CalciMedica

In related news, Director Fred A. Middleton purchased 49,794 shares of CalciMedica stock in a transaction dated Thursday, June 25th. The stock was purchased at an average cost of $4.00 per share, for a total transaction of $199,176.00. Following the completion of the acquisition, the director directly owned 212,654 shares of the company’s stock, valued at $850,616. The trade was a 30.57% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 28.25% of the company’s stock.

Hedge Funds Weigh In On CalciMedica

Hedge funds and other institutional investors have recently bought and sold shares of the stock. 180 Wealth Advisors LLC raised its holdings in shares of CalciMedica by 297.2% during the first quarter. 180 Wealth Advisors LLC now owns 126,500 shares of the company’s stock valued at $68,000 after purchasing an additional 94,650 shares during the last quarter. Boothbay Fund Management LLC purchased a new stake in CalciMedica in the fourth quarter worth approximately $506,000. Renaissance Technologies LLC boosted its holdings in CalciMedica by 45.0% in the first quarter. Renaissance Technologies LLC now owns 128,075 shares of the company’s stock worth $69,000 after purchasing an additional 39,775 shares during the last quarter. Envestnet Asset Management Inc. grew its position in CalciMedica by 58.2% in the 2nd quarter. Envestnet Asset Management Inc. now owns 93,433 shares of the company’s stock worth $149,000 after purchasing an additional 34,386 shares during the period. Finally, Jane Street Group LLC bought a new stake in CalciMedica in the 4th quarter worth approximately $127,000.

CalciMedica Stock Down 6.6%

CALC stock opened at $1.98 on Friday. The stock has a market capitalization of $13.52 million, a P/E ratio of -0.29 and a beta of 0.83. The company has a debt-to-equity ratio of 1.67, a current ratio of 5.58 and a quick ratio of 5.58. CalciMedica has a 1-year low of $1.91 and a 1-year high of $36.00. The business has a fifty day moving average price of $3.31 and a 200-day moving average price of $3.43.

CalciMedica (NASDAQ:CALC) last released its quarterly earnings data on Tuesday, August 11th. The company reported ($0.45) EPS for the quarter, beating the consensus estimate of ($1.42) by $0.97. Equities analysts forecast that CalciMedica will post -5.25 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts recently commented on the stock. Weiss Ratings raised shares of CalciMedica from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, August 27th. Wall Street Zen cut shares of CalciMedica from a “sell” rating to a “strong sell” rating in a report on Saturday. HC Wainwright reiterated a “neutral” rating on shares of CalciMedica in a research note on Wednesday, July 29th. UBS Group reiterated a “neutral” rating on shares of CalciMedica in a report on Thursday, August 13th. Finally, Guggenheim initiated coverage on shares of CalciMedica in a report on Thursday, August 20th. They set a “buy” rating on the stock. Two research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $50.00.

CalciMedica Company Profile

CalciMedica, Inc (NASDAQ:CALC) is a clinical-stage biopharmaceutical company focused on developing therapies that modulate calcium-mediated inflammatory pathways. Headquartered in Northbrook, Illinois, the company applies proprietary ion channel technology to address severe inflammatory disorders driven by dysregulated immune responses.

The company’s lead product candidate, Auxora™, is a selective inhibitor of calcium release-activated calcium (CRAC) channels. Auxora is being evaluated in clinical trials for the treatment of acute pancreatitis associated with systemic inflammatory response syndrome (SIRS) and acute respiratory distress syndrome (ARDS) in patients with severe pulmonary conditions, including COVID-19 pneumonia.